CN105878230A - New application of fucoxanthin to eyesight protection - Google Patents
New application of fucoxanthin to eyesight protection Download PDFInfo
- Publication number
- CN105878230A CN105878230A CN201610320935.7A CN201610320935A CN105878230A CN 105878230 A CN105878230 A CN 105878230A CN 201610320935 A CN201610320935 A CN 201610320935A CN 105878230 A CN105878230 A CN 105878230A
- Authority
- CN
- China
- Prior art keywords
- fucoxanthin
- food
- medicine
- vision
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 title claims abstract description 51
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 230000004438 eyesight Effects 0.000 title claims abstract description 30
- 235000013305 food Nutrition 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 241000199919 Phaeophyceae Species 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 241000195493 Cryptophyta Species 0.000 claims description 4
- 241000264279 Sargassum fusiforme Species 0.000 claims description 2
- 241000593522 Sargassum thunbergii Species 0.000 claims description 2
- 239000008297 liquid dosage form Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 210000001525 retina Anatomy 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 11
- 230000005855 radiation Effects 0.000 abstract description 6
- 230000008832 photodamage Effects 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract 2
- 230000006870 function Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 238000005286 illumination Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000700112 Chinchilla Species 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000004243 retinal function Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000009514 concussion Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 230000004379 myopia Effects 0.000 description 3
- 208000001491 myopia Diseases 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004300 dark adaptation Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000009659 non-destructive testing Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004262 retinal health Effects 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940032021 tetramune Drugs 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of fucoxanthin to preparation of medicines or food for protecting eyesight. Experiments confirm that fucoxanthin has the effect of protecting retinas from light damage and can effectively prevent excessive light radiation of computers, widescreen mobile phones, LED (light-emitting diode) lamps, and the like from damaging eyesight. When used for preparing medicines or food for protecting eyesight, fucoxanthin has the advantages that fucoxanthin is green and safe, has no limit to edible amount and is suitable for any population.
Description
Technical field
The present invention relates to technical field of health care food, particularly relate to the fucoxanthin new application for sight protectio.
Background technology
Vision impairment has become current prominent public health problem.According to World Health Organization's current research report, the most entirely
Ball about 1,400,000,000 people suffers from myopia, will increase to 2,500,000,000 to the year two thousand twenty.Wherein, China's myopia population ratio reaches 47%, with the U.S.
(42%), Japan's (46%), Singapore's (59%) and China Hong Kong & Taiwan areas (56%) equally, belong to whole world Shortsightedness prevalence together the highest
Region.It addition, according to internal authority organ of survey Multi-SponsorSurveys in a investigation report of issue in 2008
Display, it is uncomfortable to there are eyes in 50% adult；Nighttime driving, daytime goes on a tour, daytime drives, play in seashore or steer a ship and
When using the situations such as computer, crowd's ratio of eyes discomfort has respectively reached 81%, 41%, 39%, 26% and 25%.Research table
Bright, the retinal function disorder that excess light radiation causes is to cause above VI key.Therefore, safe and efficient
Retina protection plan is extremely urgent.
Fucoxanthin is the secondary metabolite that Brown algae adapts to ocean extreme path environment.Now there are some researches show, fucoxanthin not only has
There is prominent antioxidant activity 13.5 times of vitamin E (its antioxidant activity reach), also there is fat-reducing, antitumor, pre-
The multiple physiologically actives such as anti-cardiovascular disease, blood sugar lowering, antiinflammatory.But, about the functional study of fucoxanthin sight protectio
And Related product is developed, and there is not been reported.
Summary of the invention
It is an object of the invention to provide a kind of green safety, without edible quantitative limitation, it is adaptable to the fucoxanthin of any crowd
Eyesight protection function food or medicine.
For achieving the above object, the present invention provides fucoxanthin to be used for preparing medicine or the purposes of food of protection vision.
Further, medicine or the food of described protection vision contains fucoxanthin.
Further, in the medicine of described protection vision or food fucoxanthin weight content no less than 20%.
Further, medicine or the food of described protection vision can be tablet, capsule, electuary or liquid dosage form.
Further, described fucoxanthin derives from edible Brown algae.
Further, described edible Brown algae is Thallus Laminariae (Thallus Eckloniae), Thallus Laminariae, Sargassum fusiforme (Harv.) Setch, sargassum thunbergii and microsphere algae.
The vision impairment crowd caused for video frequency terminal apparatus such as current life-time service computer, widescreen mobile phones gets more and more, market
On great demand to the health food that can effectively prevent retina photodamage, the present invention chooses to be had than phylloxanthin, cryptoxanthin
The more preferable fucoxanthin of effect is primary raw material, produces the series protection food of human body retinal health or health food, as capsule,
Tablet, electuary, beverage or leisure food, this product efficacy substantially, green natural, be suitable for the numerous consumer groups.
Described fucoxanthin is to have authorized patent of invention by the present inventor's early stage " it is yellow with rock algae that a kind of enzyme process prepares Brown algae fucosan
The method of element " (patent No.: ZL201310142757.X) method of recording is prepared.
Research shows, the asthenopia that the video display terminal equipment such as life-time service computer, widescreen mobile phone causes is close with excess light radiation
Relevant.Retina is the place that visible ray focuses on, and excess light radiation can cause the polyunsaturated fatty acid in retina to occur
Lipid peroxidation, thus destroying retinal physiological structure, cause the oxidative damage of photoreceptor cell，photosensory cell and retinal pigment epithelium
Even apoptosis.Therefore, it is possible to effectively resist excess light radiation, amphiblestroid harm, functional factor must be provided simultaneously with outstanding
Antioxidant activity and the condition of light filtration.Fucoxanthin not only has long-chain unsaturated double-bond structure, possibly together with third
The special constructions such as diene, alkylene oxide, acetyl group so that it is antioxidant activity is greatly improved, its antioxidant activity is that dimension is raw
13.5 times of element E；In terms of light filtration, the characteristic absorption spectrum scope of fucoxanthin is 350-550nm (maximum suction
Receive spectrum: 450nm), and this wave band visible ray just causes the part of retina photodamage, therefore, fucoxanthin can be effective
Realized amphiblestroid protection by quencher excess light energy.Additionally, the raw materials used edible seaweed that derives from of product of the present invention, green
Color safety, without edible quantitative limitation, it is adaptable to any crowd.
Accompanying drawing explanation
Fig. 1 is the dark suitable ERG figure of fucoxanthin protection retina rod cell effect；
Fig. 2 is the bright suitable ERG figure of fucoxanthin protection retinal cones cell effect；
Fig. 3 is the maximum hybrid reaction ERG figure of fucoxanthin suppression retinal photoreceptor cells apoptosis effect；
Fig. 4 is the current potential concussion ERG figure that fucoxanthin improves retina blood microcirculation functions.
Detailed description of the invention
Embodiments of the invention are described below in detail, and the example of described embodiment is shown in the drawings, the most identical
Or similar label represents same or similar element or has the element of same or like function.Retouch below with reference to accompanying drawing
The embodiment stated is exemplary, it is intended to is used for explaining the present invention, and is not considered as limiting the invention.In embodiment
Unreceipted concrete technology or condition person, according to the technology described by the document in this area or condition or according to product description
Carry out.Agents useful for same or instrument unreceipted production firm person, be can by city available from conventional products.
Embodiment 1: beverage class fucoxanthin eyesight protection function food or the preparation of medicine
With fucoxanthin as raw material (fucoxanthin content is 30%), by weighing, redissolution, emulsifying, seasoning, sterilize, wrap
The production technologies such as dress, obtain beverage class fucoxanthin eyesight protection function food or medicine.
Embodiment 2 tablet class fucoxanthin eyesight protection function food or the preparation of medicine
With fucoxanthin as raw material (fucoxanthin content is 40%), by weighing, allocate, be dried, pelletizing, tabletting, bag
The production technologies such as dress, obtain tablet class fucoxanthin eyesight protection function food or medicine.
Embodiment 3 capsule class fucoxanthin eyesight protection function food or the preparation of medicine
With fucoxanthin as raw material (fucoxanthin content is 50%), produce by weighing, allocate, be dried, make capsule etc.
Technique, obtains capsule class fucoxanthin eyesight protection function food or medicine.
Embodiment 4 electuary class fucoxanthin eyesight protection function food or the preparation of medicine
With fucoxanthin as raw material (fucoxanthin content is 20%), by weighing, allocate, be dried, pelletizing, packaging etc. raw
Production. art, obtains electuary class fucoxanthin eyesight protection function food or medicine.
Embodiment 5: functional evaluation is tested:
Given the test agent: the embodiment of the present invention 4 preparation.
Laboratory animal and feeding environment: SPF level Chinchilla Rabbit, male and female half and half, body weight 2.0 ± 0.2kg, given birth to by Beijing the Temple of Heaven
Tetramune limited company animal center provides (quality certification number is SCXK (capital) 2004-0002).Room ventilation condition is good
Good, normal day-night change (8:00am-8:00pm), relative humidity is 55 ± 5%, room temperature: 23 ± 2 DEG C.
Dose design: laboratory animal is given daily dose,equivalent=medicine adult amount ÷ adult's body weight (in terms of 60kg) × rabbit
Body weight × 2.3 times.
Sample treatment: Example 4 preparation is as test sample.
Experimental technique: 28 Chinchilla Rabbit adaptabilities are raised one week, free choice feeding.It is randomly divided into 3 groups by body weight after 1 week,
I.e. normal group, model group, fucoxanthin intervention group, often 7 experimental animals of group.Continue to feed 2 weeks by following dosage: just
Often group given low every day is 2.5mL water, and model group given low every day is 2.5mL water, fucoxanthin intervention group every day
Given low is 2.5g sample.After 2 weeks, carry out illumination experiment.Illumination experiment uses self-control lighting box: lighting box is a size of
50 × 40 × 30cm, bottom surface and surrounding are mirror, and on angle, four, side, a piece cool white light source fluorescent tube of each installation, makes
In obtaining lighting box, all directions illuminance is 15000 ± 1000lux (TES-1332A illumination meter mensuration).Model group, rock algae
Flavin intervention group Chinchilla Rabbit after dark adaptation process 24h, uses Tropicamide and Phenylephrine eye drip in 60-100lux luminous environment
Liquid carries out mydriasis to eyes, and 20min is placed in self-control lighting box and starts illumination, and in each lighting box, interior placement one is livid purple
Blue rabbit, illumination 2h, it is not intended to Chinchilla Rabbit movable.Whole During Illumination keeps ventilating, it is ensured that illumination the temperature inside the box is maintained at
The relative isoperibol of 21-24 DEG C.After photo-irradiation treatment terminates, experimental animal is sent back to and is carried out dark adaptation process in Animal House.Press
Aforementioned given low and ingestion types continue to raise each treated animal 7 days, and physiograph ERG is to each treated animal then to use TV to feel
Retinal function detect.
Experimental result: TV feels that physiograph ERG can effectively realize the Non-Destructive Testing that retinal function is evaluated, and is clinical diagnosis
The effective ways of retina injury.Wherein, what dark suitable ERG testing result reflected is the physiological function of retina rod cell；
What bright suitable ERG reflected is the physiological function of retinal cones cell；Maximum hybrid reaction ERG reflection is that retinal photoreceptor is thin
The apoptosis situation of born of the same parents' (rod cell+cone cell)；Current potential concussion ERG reflection is retina blood microcirculation situation.Real
Test result as it can be seen, be can be seen that (Fig. 1 is the dark suitable of fucoxanthin protection retina rod cell effect by Fig. 1 Fig. 4
ERG schemes；Fig. 2 is the bright suitable ERG figure of fucoxanthin protection retinal cones cell effect；Fig. 3 is that fucoxanthin suppression regards
The maximum hybrid reaction ERG figure of nethike embrane photoperiod sensitivity gene effect；Fig. 4 is that fucoxanthin improves retina blood microcirculation merit
The current potential concussion ERG figure of effect), relatively blank group Chinchilla Rabbit retina ERG testing result, model group retina ERG's is upper
State index all to occur being remarkably decreased, illustrate that retinal function occurs in that substantially damage.After fucoxanthin intervention processes, ERG is each
Item parameter has obtained obvious recovery, illustrates that retinal function has obtained effective protection.Result above confirms, test sample has
Effect of protection retina photodamage, can effectively prevent the excess light radiation damages to vision such as computer, widescreen mobile phone, LED.
The sample of embodiment 1-3 gained all can make animal retina function be effectively protected, and has protection retina photodamage
Effect, can effectively prevent the excess light radiation effect to the damage of vision such as computer, widescreen mobile phone, LED.
Although above it has been shown and described that embodiments of the invention, it is to be understood that above-described embodiment is exemplary,
Being not considered as limiting the invention, those of ordinary skill in the art is without departing from the principle of the present invention and the situation of objective
Under above-described embodiment can be changed within the scope of the invention, revise, replace and modification.
Claims (6)
1. fucoxanthin is for preparing medicine or the purposes of food of protection vision.
2. medicine or the purposes of food of vision is protected in preparation described in claim 1, it is characterised in that the medicine of described protection vision
Or food contains fucoxanthin.
3. medicine or the purposes of food of vision is protected in preparation described in claim 2, it is characterised in that the medicine of described protection vision
Or fucoxanthin weight content is no less than 20% in food.
4. medicine or the purposes of food of vision is protected in preparation described in claim 2, it is characterised in that the medicine of described protection vision
Or food can be tablet, capsule, electuary or liquid dosage form.
5. medicine or the purposes of food of vision is protected in preparation described in claim 2, it is characterised in that described fucoxanthin derives from
Edible Brown algae.
6. medicine or the purposes of food of vision is protected in preparation described in claim 5, it is characterised in that described edible Brown algae is sea
Band, Thallus Laminariae, Sargassum fusiforme (Harv.) Setch, sargassum thunbergii and microsphere algae.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610297596 | 2016-05-07 | ||
| CN2016102975965 | 2016-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105878230A true CN105878230A (en) | 2016-08-24 |
Family
ID=56717639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610320935.7A Pending CN105878230A (en) | 2016-05-07 | 2016-05-14 | New application of fucoxanthin to eyesight protection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105878230A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114939142A (en) * | 2022-05-10 | 2022-08-26 | 仙乐健康科技股份有限公司 | Composition for resisting blue light |
| CN117137941A (en) * | 2023-09-20 | 2023-12-01 | 威海海高园明睿智琳生物科技有限公司 | A radiation-proof seaweed extract composition |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102911138A (en) * | 2012-08-25 | 2013-02-06 | 国家海洋局第一海洋研究所 | Method for extracting and purifying fucoxanthin from brown alga |
| CN103232552A (en) * | 2013-04-24 | 2013-08-07 | 集美大学 | Method for preparing brown algae fucosan and fucoxanthin in enzymic way |
| CN103833692A (en) * | 2014-02-21 | 2014-06-04 | 宁波大学 | Method for extracting high-purity fucoxanthin from seaweeds |
| CN104003962A (en) * | 2014-05-16 | 2014-08-27 | 集美大学 | Preparation method and application of alga xanthophyll |
| CN104001180A (en) * | 2014-05-16 | 2014-08-27 | 集美大学 | Preparation method of alga natural antioxidant |
-
2016
- 2016-05-14 CN CN201610320935.7A patent/CN105878230A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102911138A (en) * | 2012-08-25 | 2013-02-06 | 国家海洋局第一海洋研究所 | Method for extracting and purifying fucoxanthin from brown alga |
| CN103232552A (en) * | 2013-04-24 | 2013-08-07 | 集美大学 | Method for preparing brown algae fucosan and fucoxanthin in enzymic way |
| CN103833692A (en) * | 2014-02-21 | 2014-06-04 | 宁波大学 | Method for extracting high-purity fucoxanthin from seaweeds |
| CN104003962A (en) * | 2014-05-16 | 2014-08-27 | 集美大学 | Preparation method and application of alga xanthophyll |
| CN104001180A (en) * | 2014-05-16 | 2014-08-27 | 集美大学 | Preparation method of alga natural antioxidant |
Non-Patent Citations (1)
| Title |
|---|
| YIXIANG LIU 等: "Protective Effect of Fucoxanthin Isolated from Laminaria japonica against Visible Light-Induced Retinal Damage Both in Vitro and in Vivo", 《J AGRIC FOOD CHEM》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114939142A (en) * | 2022-05-10 | 2022-08-26 | 仙乐健康科技股份有限公司 | Composition for resisting blue light |
| CN114939142B (en) * | 2022-05-10 | 2023-12-26 | 仙乐健康科技股份有限公司 | Composition for resisting blue light |
| CN117137941A (en) * | 2023-09-20 | 2023-12-01 | 威海海高园明睿智琳生物科技有限公司 | A radiation-proof seaweed extract composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103734712B (en) | Eye-protecting blueberry-raspberry functional food | |
| Chapman | Vitamin a: history, current uses, and controversies | |
| Gazzolo et al. | Early pediatric benefit of lutein for maturing eyes and brain—an overview | |
| CA2809071C (en) | Composition and method of manufacture | |
| CN109845868A (en) | A kind of lutein ester pressed candy and preparation method thereof improving visual fatigue | |
| CN106138199A (en) | A kind of compound prescription that eyes nutrition protection vision is provided and preparation method thereof | |
| US20220039425A1 (en) | Herbal confectionery candy for eyesight improving | |
| CN105878230A (en) | New application of fucoxanthin to eyesight protection | |
| CN106721835A (en) | A kind of solid beverage for alleviating visual fatigue | |
| CN105996027B (en) | A kind of functional food of liver protection and eyesight | |
| CN108354180A (en) | A kind of composition and its application for helping to alleviate blue ray radiation injury | |
| CN105520137B (en) | It is a kind of that there is the health food alleviated visual fatigue and protect visual function | |
| US10532035B2 (en) | Methods for improvement of visual function and compositions used therein | |
| CA2986975A1 (en) | Extract of cordyceps cicadae and its use for the manufacture of pharmaceutical composition for at least one of the prevention, delaying and treatment of cataracts | |
| JP2017519048A (en) | Pharmaceutical composition containing Spirulina maxima extract as an active ingredient for preventing and treating retinal diseases | |
| Agarwal et al. | Severe ocular injury resulting from chuna packets | |
| CN106692259A (en) | Composition for improving glare stimulation | |
| CN108991207A (en) | A kind of antarctic krill oil interlayer type gel candy compound prescription | |
| Kamal et al. | Eye sight and carotenoids | |
| US20070082066A1 (en) | Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity | |
| Kuo et al. | Food colloid-based delivery systems for tackling age-related macular degeneration by enhancing carotenoid bioavailability: A review | |
| CN110755384B (en) | Effervescent granules containing lutein ester | |
| CN113796479A (en) | Eye-protecting beverage formula and processing method | |
| Madke et al. | Isotretinoin-induced night blindness | |
| US20200289428A1 (en) | Methods of protecting the eye health of children exposed to blue and white light |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160824 |
|
| RJ01 | Rejection of invention patent application after publication |